AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia
Background & Aims
Methods
Results
Conclusions
Executive Summary
| Recommendation 1: In individuals with BE with HGD, the AGA recommends EET over surveillance. (Strong recommendation, moderate certainty of evidence) |
| Implementation Considerations:•After completion of EET, surveillance should be performed at 3, 6, and 12 mo, then annually.•Surveillance endoscopies after EET should obtain targeted tissue sampling of visible lesions and random biopsies of the cardia and distal 2 cm of the tubular esophagus. |
| Recommendation 2: In individuals with BE with LGD, the AGA suggests for EET over surveillance. Patients who place a higher value on the well-defined harms and lower value on the benefits (which are uncertain) regarding reduction of esophageal cancer mortality would reasonably select surveillance endoscopy. (Conditional recommendation, low certainty of evidence) |
| Implementation Considerations:•After completion of EET, surveillance should be performed at years 1 and 3 after CEIM, then revert to surveillance intervals used in NDBE.•The tissue sampling protocol during surveillance should be performed the same as in surveillance after EET for HGD. |
| Recommendation 3: In individuals with NDBE, the AGA suggests against the routine use of EET. (Conditional recommendation, very low certainty of evidence) |
| Recommendation 4: In patients undergoing EET, the AGA suggests resection of visible lesions followed by ablation of the remaining BE segment over resection of the entire BE segment. (Conditional recommendation, very low certainty of evidence) |
| Implementation Considerations:•In patients with only a small area of BE beyond the visible lesion, completion endoscopic resection in the same setting is acceptable and may be preferred over repeated procedures to perform ablation.•RFA is the preferred ablative modality. |
| Recommendation 5: In individuals with BE with visible neoplastic lesions that are undergoing endoscopic resection, the AGA suggests the use of either EMR or ESD based on lesion characteristics. (Conditional recommendation, very low certainty of evidence) |
| Implementation Considerations:•Patients suspected of having T1 EAC should be referred for consideration of EET.•Endoscopic resection is the test of choice over endoscopic ultrasound for distinguishing EAC from HGD and for staging depth of invasion in early cancer.•The vast majority of neoplastic lesions may be managed with EMR rather than ESD.•Patients with large bulky neoplastic lesions or lesions highly suspicious of at least T1b invasion (for instance those with depressed, Paris IIc, or IIa+c lesions) and deemed candidates for endoscopic resection might benefit from ESD over EMR.•Patients with previously failed EMR might benefit from ESD.
|

